{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:53:59Z","timestamp":1789588439632,"version":"build-2803163510"},"reference-count":59,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Treatment with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has revolutionized disease management and has transformed CML from a life-threatening disease to a chronic condition for many patients. However, overcoming resistance, particularly related to leukemic stem cells (LSC) that can persist even when the bulk of the leukemic cells are eliminated, remains a significant challenge. Methods: K562 and KU812 cell lines were treated in vitro with the TKI Imatinib (IM). Gene expression, protein analysis, and metabolomic screening were conducted to investigate the ability of the drug to enhance stem cell (SC) features. Moreover, a gene ontology analysis was performed on different available datasets, to further consolidate our data. Results: 48 h of IM treatment can significantly increase the expression of genes related to SC self-renewal, particularly SOX2 and OCT 3\/4. Interestingly, these modulations occur in cells that remain alive after drug treatment and that displayed features consistent with leukemia stem-like CML cells, suggesting that SC genes levels are crucial even in cell population survived upon TKI treatment. Moreover, after in silico analysis of available data, we observed an enrichment of SOX2\/NANOG and OCT 3\/4 signatures after TKI treatment, thus strengthening our results. Conclusions: Our results confirmed the relevance of LSC features after TKI treatment, highlighting the need for more effective and potentially curative strategies targeting LSCs to overcome resistance in CML.<\/jats:p>","DOI":"10.3390\/jcm14020392","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T03:48:11Z","timestamp":1736480891000},"page":"392","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8805-959X","authenticated-orcid":false,"given":"Simone","family":"Rocco","sequence":"first","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, 10124 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-2248","authenticated-orcid":false,"given":"Alessandro","family":"Maglione","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, 10124 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Schiavo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, 10124 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6304-9782","authenticated-orcid":false,"given":"Alessandro","family":"Ferrando","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, 10124 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, 10124 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6346-4791","authenticated-orcid":false,"given":"Daniela","family":"Cilloni","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, 10124 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-0068","authenticated-orcid":false,"given":"Barbara","family":"Pergolizzi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, 10124 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Panuzzo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, 10124 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The Biology of Chronic Myeloid Leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia Chromosomal Breakpoints Are Clustered within a Limited Region, Bcr, on Chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular Pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Russo, D., Garcia-Gutierrez, J.V., Soverini, S., and Baccarani, M. (2020). Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061709"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in Studies of Tyrosine Kinase Inhibitors and Their Acquired Resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.scr.2018.01.038","article-title":"Imatinib-Mesylate Enhances the Maintenance of Chronic Myeloid Leukemia Stem Cell Potential in the Absence of Glucose","volume":"28","author":"Bono","year":"2018","journal-title":"Stem Cell Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic Myeloid Leukemia: 2018 Update on Diagnosis, Therapy and Monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-Line Imatinib vs Second- and Third-Generation TKIs for Chronic-Phase CML: A Systematic Review and Meta-Analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","article-title":"Imatinib Resistance in CML","volume":"274","author":"Volpe","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Carofiglio, F., Lopalco, A., Lopedota, A., Cutrignelli, A., Nicolotti, O., Denora, N., Stefanachi, A., and Leonetti, F. (2020). Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124469"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2008.17.5745","article-title":"Chronic Myeloid Leukemia Stem Cells","volume":"26","author":"Kavalerchik","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1101\/gad.1299505","article-title":"Bmi-1 Promotes Neural Stem Cell Self-Renewal and Neural Development but Not Mouse Growth and Survival by Repressing the P16 Ink4a and P19 Arf Senescence Pathways","volume":"19","author":"Molofsky","year":"2005","journal-title":"Genes Dev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2019.08.007","article-title":"SOX2 in Development and Cancer Biology","volume":"67","author":"Novak","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11523-020-00741-x","article-title":"In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor\/Stem Cell Features","volume":"15","author":"Tusa","year":"2020","journal-title":"Target. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lin, Z., Radaeva, M., Cherkasov, A., and Dong, X. (2022). Lin28 Regulates Cancer Cell Stemness for Tumour Progression. Cancers, 14.","DOI":"10.3390\/cancers14194640"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Li, C., Wen, L., Dong, J., Li, L., Huang, J., Yang, J., Liang, T., Li, T., Xia, Z., and Chen, C. (2022). Alterations in Cellular Metabolisms after TKI Therapy for Philadelphia Chromosome-Positive Leukemia in Children: A Review. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1072806"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood.2022018196","article-title":"Metabolic Adaptation to Tyrosine Kinase Inhibition in Leukemia Stem Cells","volume":"142","author":"Qiu","year":"2023","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mostazo, M.G.C., Kurrle, N., Casado, M., Fuhrmann, D., Alshamleh, I., H\u00e4upl, B., Mart\u00edn-Sanz, P., Br\u00fcne, B., Serve, H., and Schwalbe, H. (2020). Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. Cancers, 12.","DOI":"10.3390\/cancers12113443"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/s41467-023-40222-z","article-title":"Pyruvate Anaplerosis Is a Targetable Vulnerability in Persistent Leukaemic Stem Cells","volume":"14","author":"Rattigan","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Panuzzo, C., Pironi, L., Maglione, A., Rocco, S., Stanga, S., Riganti, C., Kopecka, J., Ali, M.S., Pergolizzi, B., and Bracco, E. (2023). mTORC2 Is Activated under Hypoxia and Could Support Chronic Myeloid Leukemia Stem Cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021234"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Calabrese, C., Panuzzo, C., Stanga, S., Andreani, G., Ravera, S., Maglione, A., Pironi, L., Petiti, J., Shahzad Ali, M., and Scaravaglio, P. (2020). Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores P53 Signaling by Stabilization of P53 Family Members in Leukemic Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207674"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.advms.2023.06.002","article-title":"Phenotypic and Functional Characterization of Subpopulation of Imatinib Resistant Chronic Myeloid Leukemia Cell Line","volume":"68","author":"Hekmatshoar","year":"2023","journal-title":"Adv. Med. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Casta\u00f1eda, E., Hopcroft, L., Rogers, S., Munje, C., Bittencourt-Silvestre, J., Copland, M., Vetrie, D., Holyoake, T., and J\u00f8rgensen, H. (2022). Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy. Cancers, 14.","DOI":"10.1101\/2022.06.30.498287"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G.V., Clark, N.R., and Ma\u2019ayan, A. (2013). Enrichr: Interactive and Collaborative HTML5 Gene List Enrichment Analysis Tool. BMC Bioinform., 14.","DOI":"10.1186\/1471-2105-14-128"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Trombetti, S., Cesaro, E., Catapano, R., Sessa, R., Lo Bianco, A., Izzo, P., and Grosso, M. (2021). Oxidative Stress and ROS-Mediated Signaling in Leukemia: Novel Promising Perspectives to Eradicate Chemoresistant Cells in Myeloid Leukemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052470"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Baykal-K\u00f6se, S., Acikgoz, E., Yavuz, A.S., G\u00f6n\u00fcl Geyik, \u00d6., Ate\u015f, H., Sezerman, O.U., \u00d6zsan, G.H., and Y\u00fcce, Z. (2020). Adaptive Phenotypic Modulations Lead to Therapy Resistance in Chronic Myeloid Leukemia Cells. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229104"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e1140","DOI":"10.1038\/cddis.2014.105","article-title":"Cav-1 Deletion Impaired Hematopoietic Stem Cell Function","volume":"5","author":"Bai","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 Eradicates Human Acute Myeloid Leukemic Stem Cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Panuzzo, C., Jovanovski, A., Pergolizzi, B., Pironi, L., Stanga, S., Fava, C., and Cilloni, D. (2020). Mitochondria: A Galaxy in the Hematopoietic and Leukemic Stem Cell Universe. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113928"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The Chronic Myeloid Leukemia Stem Cell: Stemming the Tide of Persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline Nilotinib: 96-Week Update of the ENESTfreedom Study","volume":"144","author":"Ross","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41571-020-0367-1","article-title":"Treatment-Free Remission in Patients with Chronic Myeloid Leukaemia","volume":"17","author":"Ross","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: When and for Whom?","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.cellsig.2013.02.013","article-title":"The Multiple Roles for Sox2 in Stem Cell Maintenance and Tumorigenesis","volume":"25","author":"Liu","year":"2013","journal-title":"Cell. Signal."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jmcb\/mjy080","article-title":"SOX2 in Cancer Stemness: Tumor Malignancy and Therapeutic Potentials","volume":"12","author":"Mamun","year":"2020","journal-title":"J. Mol. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"55624","DOI":"10.18632\/oncotarget.10954","article-title":"Hypoxia-NOTCH1-SOX2 Signaling Is Important for Maintaining Cancer Stem Cells in Ovarian Cancer","volume":"7","author":"Seo","year":"2016","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s43046-024-00209-3","article-title":"Significance of OCT3\/4 and SOX2 Antigens Expression by Leukemic Blast Cells in Adult Acute Leukemia","volume":"36","author":"Aref","year":"2024","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.leukres.2018.02.001","article-title":"Prognostic Significance of SOX2, SOX3, SOX11, SOX14 and SOX18 Gene Expression in Adult de Novo Acute Myeloid Leukemia","volume":"67","author":"Tosic","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Picot, T., Aanei, C.M., Fayard, A., Flandrin-Gresta, P., Tondeur, S., Gouttenoire, M., Tavernier-Tardy, E., Wattel, E., Guyotat, D., and Campos, L. (2017). Expression of Embryonic Stem Cell Markers in Acute Myeloid Leukemia. Tumor Biol., 39.","DOI":"10.1177\/1010428317716629"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2018-99-110679","article-title":"Single Cell Transcriptome in Chronic Myeloid Leukemia (CML): Pseudotime Analysis Reveals a Rare Population with Embryonic Stem Cell Features and Druggable Intricated Transitional Stem Cell States","volume":"132","author":"Pagliaro","year":"2018","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e26733","DOI":"10.7554\/eLife.26733","article-title":"NFATc2 Enhances Tumor-Initiating Phenotypes through the NFATc2\/SOX2\/ALDH Axis in Lung Adenocarcinoma","volume":"6","author":"Xiao","year":"2017","journal-title":"eLife"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Huang, C.-Y., Chung, Y.-H., Wu, S.-Y., Wang, H.-Y., Lin, C.-Y., Yang, T.-J., Fang, J.-M., Hu, C.-M., and Chang, Z.-F. (2024). Glutathione Determines Chronic Myeloid Leukemia Vulnerability to an Inhibitor of CMPK and TMPK. Commun. Biol., 7.","DOI":"10.1038\/s42003-024-06547-1"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Patel, S.B., Nemkov, T., D\u2019Alessandro, A., and Welner, R.S. (2022). Deciphering Metabolic Adaptability of Leukemic Stem Cells. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.846149"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1158\/0008-5472.CAN-23-1006","article-title":"Oxidative Phosphorylation Fueled by Fatty Acid Oxidation Sensitizes Leukemic Stem Cells to Cold","volume":"83","author":"Griessinger","year":"2023","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.stem.2015.08.019","article-title":"AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow","volume":"17","author":"Saito","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1158\/1078-0432.CCR-16-1903","article-title":"AMPK\u2013ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells","volume":"23","author":"Jang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/0008-5472.CAN-24-0019","article-title":"Targeting Metabolic Dependencies Fueling the TCA Cycle to Circumvent Therapy Resistance in Acute Myeloid Leukemia","volume":"84","author":"Sarry","year":"2024","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Peng, M., Huang, Y., Zhang, L., Zhao, X., and Hou, Y. (2022). Targeting Mitochondrial Oxidative Phosphorylation Eradicates Acute Myeloid Leukemic Stem Cells. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.899502"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e40492","DOI":"10.1016\/j.heliyon.2024.e40492","article-title":"Targeting Pivotal Amino Acids Metabolism for Treatment of Leukemia","volume":"10","author":"Hong","year":"2024","journal-title":"Heliyon"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2019.246306","article-title":"Recruiting TP53 to Target Chronic Myeloid Leukemia Stem Cells","volume":"105","author":"Grant","year":"2020","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.exphem.2016.02.007","article-title":"Regain Control of P53: Targeting Leukemia Stem Cells by Isoform-Specific HDAC Inhibition","volume":"44","author":"Kuo","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/jcp.22561","article-title":"The P53 Tumor Suppressor Protein Regulates Hematopoietic Stem Cell Fate","volume":"226","author":"Asai","year":"2011","journal-title":"J. Cell. Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2021-150372","article-title":"Uncoupling P53 from an Embryonic Regulome Exhausts Quiescent CML Stem Cells through Inhibition of a HIF1alpha Molecular Program","volume":"138","author":"Scott","year":"2021","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Houshmand, M., Kazemi, A., Anjam Najmedini, A., Ali, M.S., Gaidano, V., Cignetti, A., Fava, C., Cilloni, D., Saglio, G., and Circosta, P. (2021). Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245805"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1254\/jphs.13025FP","article-title":"Multi-Drug\u2013Resistant Cells Enriched From Chronic Myeloid Leukemia Cells by Doxorubicin Possess Tumor-Initiating\u2013Cell Properties","volume":"122","author":"Xin","year":"2013","journal-title":"J. Pharmacol. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/2\/392\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:26:07Z","timestamp":1759919167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/2\/392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["jcm14020392"],"URL":"https:\/\/doi.org\/10.3390\/jcm14020392","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]}}}